MHCombiotic is advancing next-generation antimicrobial technologies designed to tackle chronic infections, biofilms, and antimicrobial resistance through science-driven, non-antibiotic solutions.
Built through years of scientific research and over 18,000 formulation experiments, our proprietary Combiotic™ platform is redefining how complex wounds are treated — with safer, smarter, and resistance-resilient antimicrobial care.
MHCombiotic Inc. is a Calgary-based biotechnology company focused on advancing next-generation antimicrobial solutions for chronic infections, biofilms, and antimicrobial resistance (AMR).
Founded by Dr. Ali Pormohammad, Professor R. J. Turner, and CCrest Laboratory, the company emerged from postdoctoral research at the University of Calgary and has collaborated with Harvard University, the University of Barcelona, and leading research institutions across Canada and the United States.
Over five years of intensive research, the team screened more than 18,000 formulations, leading to the development of Combiotic™ — a proprietary antimicrobial platform engineered to support safer, smarter, and more effective infection management solutions.
ComBatic™ technologies have been evaluated through studies conducted in FDA and Health Canada-compliant laboratories, supporting the platform’s scientific and clinical advancement.
Innovation & Impact
Collectively bring over 45 years of experience in combating antibiotic resistance and pioneering antimicrobial discovery
A multidisciplinary network of researchers, biotech executives, and commercialization experts supporting the advancement of breakthrough antimicrobial technologies.
Ready when you are
Clinically validated solutions designed to disrupt biofilms, reduce infection, and support faster recovery
